How Myomin Works & Why Estrogen Levels Elevate 
Myomin by Chi Enterprises: Aromatase Inhibitor for Estrogen-Dominant Disorders
Myomin Benefits:
Myomin benefits women with high levels of estrogen or experiencing symptoms caused by high estrogen levels. Myomin benefits women experiencing symptoms caused by uterine fibroids, cysts, endometriosis, and estrogen-receptive growths.
Myomin Men?
Yes! Myomin benefits men who are experiencing high levels of estrogen. Men get high levels of circulating estrogens from environmental toxins, just like women, or from poor liver detoxification, obesity or other reasons. Myomin has shown to benefit men with specific prostate disorders. As men age, testosterone decreases and estrogen increases. Given that Myomin helps minimize estrogen formation, this indirectly increases testosterone. Learn more below about why Myomin and men work well together as men age.
Myomin Side Effects
Myomin side effects are minimal and the side effects by Myomin can be avoided:
Chang Hai Hospital studies show approximately 1% of the subjects taking Myomin experienced side effects such as nausea and bloating. These Myomin side effects go away when the Myomin dosage is reduced or when Myomin is taken with meals.
Estrogen-dominant disorders such as endometriosis, cysts, fibroids and breast cancer may benefit from taking Myomin by Dr Chi. Myomin supports the reduction of estrogen production which is why Myomin is so effective for many women in reducing uterine fibroids and reducing estrogen-sensitive cells.
Myomin is an all-natural herbal formula that can support the reduction of estrogen through Chinese herbs.The herbal ingredients of Myomin are Aralia, Smilax glabra, Curcurma zedoria, and Cyperus otundus. These herbs have been traditionally used for various female ailments and hormone related disorders. Aralia and Cyperus rotundus both help reduce estradiol. Cyperus is also effective against cervical endometriosis and cervical carcinoma. Additionally, Aralia has been found to be cytotoxic against several human cancer cell lines.
Aromatase is a key enzyme in the synthesis of estrogen. Specifically, it converts androstenedione into estrone and testosterone into estradiol. For instance, evidence shows that breast cancer and prostate cancer tissues overexpress aromatase. Inhibiting aromatase, therefore, plays an important role in suppressing the deleterious action of estrogen on hormone related conditions. This is why Myomin is so helpful in uterine fibroids and other high estrogen disorders such as endometriosis.
An in vivo study demonstrated that Myomin inhibits the aromatase enzyme in the ectopic endometrium and ovarian tissue of rats. Aromatase was expressed markedly in the untreated ectopic endometrium of the positive control group. On the other hand, aromatase expression significantly decreased in the ectopicendometrium of the Myomin group after 28 days.
Similar to the ectopic endometrium tissue, aromatase expression was remarkably high in the untreated ovaries of the positive control group. After 28 days of therapy with Myomin, aromatase expression was significantly reduced in the ovarian tissue.
Image analysis of both the ectopic endometrium and ovarian tissues yielded elevated aromatase expression in the positive control group (108.9 and 149.8,respectively) in both tissues. After administration with Myomin for 28 days, aromatase expression reduced to 34.7 in the endometrium and 47.0 in the ovary. This translates to a 100% reduction of aromatase expression in the endometrium and an 85.6% reduction in the ovary compared to the negative control group.
Myomin has three functions:
- Myomin inhibits the aromatase enzyme, effectively reducing estradiol levels by preventing the conversion of androgens to estrone and estradiol. This allows testosterone and estriol (the good estrogen) to accumulate. Aromatase inhibition has become a worthwhile target in many estrogen-dominant disorders
- Myomin competes with estradiol at the estrogen receptors. This function is particularly effective in cases where estrogen receptors are fully stimulated (e.g. after HRT). Competing with estradiol prevents estradiol from binding to receptors. As a result, proliferation of cells is avoided and abnormal growth inhibited.
- Myomin increases interferon (IFN) and interleukin-2 (IL-2). IL-2 induces the proliferation of immune cells, enhancing the body's ability to kill tumor cells. IFN stimulates natural killer cells and is active against tumors.
Myomin Reduces Estradiol Levels
One study performed at the Shanghai Medical School illustrates the effect of Myomin on estradiol levels of mice during pregnancy – a period when estradiol levels are especially high. Two groups of 12 mice each were used in the study. One group was used as the control. The other group was given Myomin beginning 15 days into pregnancy. Three days later (on the 18 th day of the study), the average estradiol level of the Myomin group was 7.22pg/ml, approximately seven times less than the control group. After 6 days of taking Myomin (on the 21 st day of the study), their average estradiol level was 8.81pg/ml while it was 85.98 pg/ml for the control group.
In another study, 90 female mice were divided into three groups. Each group was then given Myomin for 30, 60 and 180 days, respectively. The average estradiol levels after each period was 50.6, 36.6, and 32.4 pg/ml, respectively. After 180 days, the estradiol level stabilized. These results demonstrate long-term use of Myomin reduces estradiol in such a way that it maintains around the normal level. No side effects were reported in this study.
A human study involved 60 postmenopausal women with cysts and/or fibroids. Postmenopausal women were studied because their estradiol levels are more stable than those of premenopausal women. Initially, the average estradiol level was 74.52 pg/ml. After only 10 days on Myomin, their average estradiol level reduced to 38.84 pg/ml. The fibroids, cysts and associated pain gradually reduced.
Myomin and Estrogen Dominant Disorders
A study from Chang Hai Hospital involved 75 cases of fibrocystic breasts (70 women ages 18 to 52 years old and 5 men ages 62 to 64 years old). Sixty five percent of the women were under 35 years old. 25 cases were in the control group while 50 cases were in the Myomin group. Results of the study revealed that, in 14 cases, the fibrocystic breast completely cleared after 1 month of taking Myomin while, in 16 cases, the fibrocystic breast reduced 50% in size. Among the five men in the study, the cysts cleared completely in 3 cases. Overall, the effectiveness rate of Myomin is more than 60%, compared to the control group's 12% rate. In the Myomin group, in 48 out of 50 cases,associated pain cleared or tremendously reduced (p value <0.05) while in the control group, pain reduced in only 12 out of 25 cases.
A 1994 clinical study was conducted on 255 patients with ovarian cysts and endometriosis. After 5 months, Myomin was effective on 147 patients (57%) while some improvements was observed in 87 patients (34.1%). No effect was observed in only 21 patients.
Another study was conducted on both pre- and postmenopausal women with ovarian cysts. In one study from the Chang Hai Hospital in Shanghai, China, 85 female patients with ovarian cysts were involved, with ages ranging from 27to 64 years old (more than 50% of them between 34 and 45 years old). Out of the 85, 40 cases were related to endometriosis (hyatidiform cyst), 44 cases were simple ovarian cysts and 1 was a case of ovarian cancer. After 1 to 3 courses of the herbal formula, the cysts and symptoms of 15 patients completely cleared with no recurrence 3 months after the study. In 34 patients, the size of the cyst reduced by 50% and some of the associated symptoms were relieved.
Y. Dikansky, DDS from NY, has a 38 year old female patient with an ovarian cyst for 8 years. The cyst was 3.7x6x2. After 3 months on Myomin, the cyst cleared.
A 2000 study at the Shanghai Medical School was performed on 60 patients with small uterine fibroids. It revealed that if Myomin is used in combination with Revivin, it is 69.2% effective on uterine fibroids that exceed 2.5cm³ in size. Another alternative would be to combine Myomin with Angiostop, an angiogenesis inhibitor.
The potential applications of aromatase inhibitors in many health conditions are continually increasing. They have been shown to reduce the risk of recurrent breast cancer, especially when used for a longer period. However, the aromatase inhibitor drugs in the market today are indicated for postmenopausal women only. This is very limiting especially since more and more premenopausal women are developing estrogen-related conditions. It is for this reason that the results of these studies on Myomin are significant. As stated before, Myomin has been used in clinical studies and found to be effective in both premenopausal and postmenopausal women with ovarian cysts, fibrocystic breast and endometriosis as well as in men with fibrocystic breast. It is able to produce these favourable results by inhibiting aromatase and consequently reducing estrogen levels.
Myomin and Men: More Information:
Aromatase inhibition is important in men as well. As men age, testosterone is being more readily converted to estrogen through the aromatase enzyme. Increased estrogen levels can lead to problems such as prostate cancer, prostatitis, and even gynecomastia. Evidence suggests that local aromatase expression in the prostate increases malignancy. In fact, the level of aromatase expression in malignant prostate tissue is comparable to that in breast cancer tissue. As a result, local estrogen levels are also promoted at the prostate tumor site, increasing growth. Aromatase inhibitors like Myomin will help block the action of aromatase, thereby minimizing the depletion of testosterone and reducing estrogen levels.
Myomin for Relief of Menopausal Symptoms
Myomin has also been reported to be effective in reducing the severity and frequency of hot flashes in some women. Although its exact mechanism on this particular function remains to be elucidated, it may be explained by Myomin's ability to compete with estrogen at the cells' estrogen receptors. It should be noted, however, that some women experience worsening of symptoms with Myomin. This is probably due to very low levels of estrogen in these women.
Myomin for Abdominal Fat
An aromatase inhibitor like Myomin can also reduce abdominal fat. Abdominal obesity is associated with decreased testosterone levels (or hypogonadism) and increased estradiol levels. Hypogonadism leads to the deposition of fat in the abdomen. As fat accumulates, aromatase activity increases at the site, causing more testosterone to be converted into estradiol. Taking testosterone or DHEA supplements is not enough because if aromatase is uncontrolled, then testosterone and DHEA will eventually be converted to estradiol. Adding anaromatase inhibitor like Myomin blocks the action of aromatase, effectively preventing the testosterone from being converted into estradiol. This leads to more muscle mass and the loss of abdominal weight.
Myomin is an herbal formula that is both an anti-estrogen agent and an aromatase inhibitor. This formula combined with Angiostop, an angiogenesis inhibitor, presents an effective combination for breast cancer. Revivin may also be added to help kill cancer cells. To boost the immune system, Asparagus Extract and Reishi Spore Extract are recommended.
Myomin And Chi-F For PCOS
PCOS is associated with an excess level of the androgens testosterone, androstenedione, and DHEA. This leads to a condition of excess hair growth, which is common in some women with PCOS.
Managing PCOS involves inducing ovulation, making the menstrual cycle normal and reducing associated symptoms. In many cases, supplementation with progesterone is recommended. However, there are may be future risks involved.
In the biochemical pathway of sex hormones, progesterone and androgens are precursors to estrogen. This means that the higher the amount of progesterone and androgens, the more estrogen is produced (through the action of the aromatase enzyme). Excess estrogen is common in obese women. As fat accumulates, aromatase activity increases, leading to the conversion of more androgens into estrogen.
Myomin is an ideal supplement for normalizing estrogen levels. It acts by inhibiting the aromatase enzyme, stopping the conversion of androgens into estrogen. Numerous studies have shown that Myomin is able to reduce estrogen levels in as little as 10 days. It also reduces ovarian cysts.
Because of the imbalance of hormones in PCOS, Chi-F is also recommended. Studies have shown that Chi-F balances hormones in the body, making it effective for reducing symptoms associated with menstrual abnormalities in women.
The Development of Myomin, a Chinese herbal formula, has been clinically shown to reduce fibroid cysts, to have effective inhibition rates and improve immunity. It contains Curcuma zedoaria (Berg.) Rosc., Cyperus rotundus L.,Smilax glabra Roxb., Areca catechu L. (Pericarpium arecae), and Aralia Dasyphylla Miq. Myomin has also been proven to induce interferon, tumor necrosis factor, interleukin-2, and lymphatic toxin. This herbal supplement is especially beneficial when treating ovarian poly-cysts as well as mammary ductal hyperplasia. In addition, it has been found to be effective in treating breast cancer as well as cervical cancer. Through clinical data it has been shown that Myomin is excellent for treating endometriosis and does not result in negative side effects such as weight gain or dry vagina. For best results, Myomin should be taken 3 times a day, 2-3 capsules each time. It should only betaken 30 minutes after each meal.
In another respect, Myomin can reduce myoma symptoms and significantly reduce the size of the growths. Myomin is good for maintaining good health in female organs such as the breasts, uterus and ovaries. This amazing mixture has also been shown to prevent ectopic pregnancy, adjust irregular menstrual cycles, prevent post-operative adhesion of organs and now has been found to work on skin tumors as well. Myomin works best on tumors no larger than 2-3cmin each dimension. It is excellent for kidney and thyroid cysts. Improvements should be seen within 2-3 months of treatment. In regard to cervical cancer, aspeedy rate of improvement (within 4-6 months) should also be observed. The product works to increase circulation and dissolve clots, detoxifying thesystem and mitigating fever. It is excellent for alleviation of enlarged livers and spleens and cirrhosis.
Clinical Studies:
In an experiment done to test the effectiveness of Myomin, 100 patients were given Myomin and after a 2-3 month treatment period, two-thirds of tumors were reduced and the overall volume of menstrual fluid was reduced by 50%. The total effectiveness rate was 44% while the control group showed only 15% effectiveness using conventional treatment only.
Myomin also helps to shrink fibroids and so is also beneficial for patients who suffer from cysts found in the ovary, kidney, liver, thyroid and breasts.Clinical studies have shown that Myomin is capable of inhibiting cysts and abnormal growths, such as tumors, as well as improving immunity, induce interferon levels, tumor necrosis factor and interleukins. The results of several hundred case studies regarding ovarian cysts show that the effectiveness of Myomin on ovarian cysts is 57.7%. In addition to being the most commonly found benign tumor on female genitalia, myoma is the most frequently observed tumor in the entire body. Myomin has been clinically shown to reduce myoma symptoms of galactoma, neurinoma, endometriosis and cysts in many organs.
Myomin for Osteoporosis and Kidney Function
Myomin has also been shown to be excellent in the improvement of osteoporosis and kidney function. In a test including 160 people (152 women and 8 men) with osteoporosis, 29% of the patients actually improved their condition with use of the product, as well as their overall bone density in a course of 2 years. Conventional calcium treatment methods showed only a 10% rate of effectiveness. And since the product is shown to be good for the kidneys, it works to prevent hair loss in those with poor kidney function. In tests conducted on over 1000 patients at the Bejing Red Cross Hospital, 86% benefited from Myomin use.
Chang Hai Hospital in Shang Hai reported 75 case studies involving fibrocystic breast disease. Five of the patients were males. Their ages ranged from 18-52 years old. The two males were 62 and 64 years years old. 65% of thegroup were under 35 years old. 50 of the patients were treated with Myomin andthe other 25 were used as controls in a double blind study. The Myomin group consisted of 38 people with both breasts afflicted. More than 60% of thefibrocysts were over 3cm. They were treated with Myomin three times a day,three capsules at a time, for up to 3 months. Within one month, 14 cases werealready improved. Totally, only 5 cases were unaffected. 90% of the cases showed improvements. 95% of the patients reported a reduction in pain. Both males and females experienced these positive results.
When taken 30 minutes after meals, 3 times a day, Myomin produces excellent results. For those with Ductal hyperplasia, Myomin successfully inhibits proliferation of the lactation ducts and the difference is noticeable within days of treatment. Its beneficial effects on ovarian cysts can be observed within one month of usage. Symptoms of abdominal pain, myoma, and irregular period and discharge cycles are all improved within 1-2 months of taking Myomin as recommended.
Additional Details of Myomin by Chi's Enterprise - 120 Capsules
Cost Per Serving: $0.75
Weight:
0.38 lbs
SKU:
003-05-020-00
Brand:
Chi's Enterprise
Delivery type:
Vegetarian Capsule
Contraindications :
Consult your physician before use
Special instructions:
Keep bottle tightly closed. Store in a cool, dry place.
MPN:
2287
UPC:
704889389583
Return Policy:
45 Day Money Back Guarantee!
Made In:
USA
October 2006 I had uterine cancer and had a Laparoscopic hysterectomy. I did not have radiation or chemo. Prior to my surgery, I was told I was making too much estrogen. Is 
